| Overall Survival | Mean | Median | 1 year % | 2 year % | 5 year % | End of the study | χ2 | p |
| Age |
|
|
|
|
|
|
|
|
| 20 - 40 | 34.5 | 37.2 | 95.8 | 60.7 | 15.7 | 7.8 |
|
|
| >40 - 60 | 46.5 | 38.6 | 96.9 | 66.3 | 31.5 | 0.0 | 6.056* | 0.048* |
| >60 | 69.1 | 79.8 | 91.7 | 91.7 | 58.9 | 19.6 |
|
|
| BMI |
|
|
|
|
|
|
|
|
| <25 | 31.7 | 24.9 | 88.9 | 55.6 | 14.8 | 0.0 | 2.117 | 0.146 |
| >25 | 45.2 | 37.2 | 96.8 | 66.5 | 30.8 | 0.0 | ||
| Menopausal status |
|
|
|
|
|
|
|
|
| Pre | 38.5 | 37.2 | 93.6 | 63.8 | 16.7 | 0.0 | 3.580 | 0.058 |
| Post | 55.1 | 42.9 | 98.1 | 72.7 | 43.9 | 0.0 | ||
| Histological type |
|
|
|
|
|
|
|
|
| Lobular | 30.0 | 30.9 | 100 | 100 | - | 25.0 | 0.006 | 0.939 |
| Ductal | 48.1 | 37.9 | 95.8 | 67.5 | 32.0 | 0.0 | ||
| Grade |
|
|
|
|
|
|
|
|
| Grade 1 + 2 | 50.8 | 41.2 | 96.5 | 71.7 | 35.7 | 0.0 | 5.429* | 0.020* |
| Grade 3 | 28.6 | 30.7 | 93.3 | 53.3 | - | 0.0 | ||
| Tumor size (cm) |
|
|
|
|
|
|
|
|
| ≤2 | 45.8 | 39.4 | 100 | 77.4 | 37.1 | 0.0 | 13.331* | 0.001* |
| 2 - 5 | 52.9 | 41.7 | 95.7 | 76.1 | 36.1 | 0.0 | ||
| >5 | 24.6 | 21.1 | 94.1 | 35.3 | 0.0 | 0.0 | ||
| Lymph node involvement |
|
|
|
|
|
| ||
| Negative | 52.7 | 45.7 | 93.8 | 73.7 | 38.3 | 0.0 | 0.167 | 0.682 |
| Positive | 45.1 | 37.2 | 96.5 | 68.0 | 30.4 | 3.6 | ||
| Number of lymph nodes |
|
|
|
|
|
| ||
| ≤3 | 50.2 | 37.7 | 96.4 | 70.5 | 39.3 | 0.0 | 0.126 | 0.723 |
| ≥4 | 44.9 | 37.9 | 95.9 | 68.2 | 27.4 | 5.3 | ||
| HER-2 status |
|
|
|
|
|
|
|
|
| Negative | 54.4 | 42.9 | 97.0 | 73.8 | 39.4 | 0.0 | 5.312* | 0.021* |
| Positive | 36.2 | 28.3 | 93.7 | 59.3 | 18.7 | 0.0 | ||
| Hormone receptors status |
|
|
|
|
|
| ||
| ER /PR negative | 38.7 | 30.7 | 94.7 | 63.2 | 23.1 | 0.0 | 1.596 | 0.207 |
| ER/PR positive | 50.4 | 39.4 | 96.2 | 71.0 | 34.1 | 0.0 | ||
| Lymph vascular invasion |
|
|
|
|
|
| ||
| Negative | 30.0 | 25.5 | 100 | 55.6 | 32.9 | 22.2 | 0.093 | 0.760 |
| Positive | 37.4 | 31.4 | 93.3 | 60.9 | 24.9 | 5.1 | ||